Allergy Therapeutics appoints Cheryl MacDiarmid to Board of Directors

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, has announced the appointment of Cheryl MacDiarmid as a Non-Executive Director of the Company, with effect from 27 October 2021. Upon appointment Cheryl will also become a member of the Audit Committee.   

Cheryl has more than 25 years’ experience in commercial roles within the global pharmaceuticals sector. She brings significant marketing, strategy and management expertise, having worked for GlaxoSmithKline (GSK) since 1993, where she has focussed mainly on the commercial aspects of the business, developing a deep knowledge of sales and marketing operations in North America. Cheryl has significant senior management experience within GSK, initially in Canada and then in the US where she led the Respiratory Business Unit and associated US operations. In 2019 Cheryl was appointed Senior Vice President and Head, Global Commercial Strategy for ViiV Healthcare, the joint venture between GSK, Pfizer and Shionogi which specialises in the development of therapies for HIV.    

Peter Jensen, Chairman of Allergy Therapeutics, commented: “We are delighted to welcome Cheryl to the Board of Allergy Therapeutics. Cheryl brings highly relevant experience, with her knowledge of the healthcare sector, expertise in marketing and commercial strategy, and her understanding of the US market, especially in the light of our recent announcement that our pivotal G306 Phase III trial is on track to commence in H2 2022 in US and Europe. I have no doubt she will be an important contributor to the Board.”

Commenting on her appointment, Cheryl MacDiarmid said: “I am delighted to be joining the Board of Allergy Therapeutics at an exciting time for the Company. I look forward to helping the Board to further strengthen Allergy’s leadership in the allergy immunotherapeutics field, providing innovative products to help people worldwide.”

Additional Disclosures

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules of Companies.

Ms Cheryl Faye MacDiarmid (aged 53) holds or has held the following current and former directorships in the past five years:

Save as set out above, no further information regarding Cheryl MacDiarmid is required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies.